.png){kind=icon}
.png){kind=icon}
Return
The 60-year evolution of lipid nanoparticles for nucleic acid delivery
.png){kind=icon}
PRE
AI
DOI：10.1038/s41573-024-00977-6.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
Delivery of genetic information to the interior of target cells in vivo has been a major challenge facing gene therapies. This barrier is now being overcome, owing in part to dramatic advances made by lipid-based systems that have led to lipid nanoparticles (LNPs) that enable delivery of nucleic acid-based vaccines and therapeutics. Examples include the clinically approved COVID-19 LNP mRNA vaccines and Onpattro (patisiran), an LNP small interfering RNA therapeutic to treat transthyretin-induced amyloidosis (hATTR). In addition, a host of promising LNP-enabled vaccines and gene therapies are in clinical development. Here, we trace this success to two streams of research conducted over the past 60 years: the discovery of the transfection properties of lipoplexes composed of positively charged cationic lipids complexed with nucleic acid cargos and the development of lipid nanoparticles using ionizable cationic lipids. The fundamental insights gained from these two streams of research offer potential delivery solutions for most forms of gene therapies. Lipid nanoparticle-based systems are increasingly being utilized for the delivery of nucleic acid-based vaccines and therapeutics. In this Perspective, Cullis and Felgner trace the evolution of these systems over the past 60 years and discuss future prospects for LNP-enabled gene therapies.
Keywords:
LARGE UNILAMELLAR VESICLES
PROLONGED CIRCULATION TIME
GLOBIN MESSENGER-RNA
IN-VIVO
GENE-TRANSFER
P-31 NMR
INTRACELLULAR DELIVERY
TRANSFECTION ACTIVITY
ASILOMAR CONFERENCE
BIOLOGICAL-ACTIVITY
Journal
IF:
101.8
Papers:
5.1K
Citations:
5.3W
